NASDAQ : NDRA
ENDRA Life Sciences Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 4.75 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.12M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.12M |
| Enterprise Value | 5.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.50M |
| Shares Outstanding | 1.50M |
| Shares Change (YoY) | +113.32% |
| Shares Change (QoQ) | +106.34% |
| Owned by Insiders (%) | 4.73% |
| Owned by Institutions (%) | 10.24% |
| Float | 1.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.10 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -152.04% |
| Return on Assets (ROA) | -77.32% |
| Return on Invested Capital (ROIC) | -94.78% |
| Return on Capital Employed (ROCE) | -92.93% |
| Weighted Average Cost of Capital (WACC) | 3.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$537,878 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.08 |
| 52-Week Price Change | -5.19% |
| 50-Day Moving Average | 5.44 |
| 200-Day Moving Average | 4.81 |
| Relative Strength Index (RSI) | 42.05 |
| Average Volume (20 Days) | 13,180 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 24,087 |
| Short Previous Month | 28,233 |
| Short % of Shares Out | 1.61% |
| Short % of Float | 1.77% |
| Short Ratio (days to cover) | 0.71 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.65M |
| Pretax Income | -5.92M |
| Net Income | -5.92M |
| EBITDA | -6.61M |
| EBIT | -6.65M |
| Earnings Per Share (EPS) | -$5.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.74M |
| Total Debt | 429,274 |
| Net Cash | 1.31M |
| Net Cash Per Share | $0.87 |
| Equity (Book Value) | 6.31M |
| Book Value Per Share | 4.21 |
| Working Capital | 4.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.82M |
| Capital Expenditures | -18,670 |
| Depreciation & Amortization | 38,551 |
| Net Borrowing | n/a |
| Free Cash Flow | -4.84M |
| FCF Per Share | -$3.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -113.32% |
| Shareholder Yield | -113.32% |
| Earnings Yield | -113.30% |
| FCF Yield | -67.96% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 7, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:35 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |